Albuminuria is a strong marker for kidney and cardiovascular risk in patients with type 2 diabetes or CKD.1, , , –5 Sodium–glucose co-transporter 2 (SGLT2) inhibitors attenuate progressive loss of kidney function and reduce the risk of kidney failure in patients with CKD and type 2 diabetes.6 SGLT2 inhibitors also reduce albuminuria in patients with type 2 diabetes and cardiovascular disease or CKD.6, –8 The reduction in albuminuria is seen early after SGLT2 inhibitor initiation and is sustained during prolonged treatment. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.